Recent Articles

 
  • Latvijas Juras medicinas centrs JSC: interim report for the 3 months of 2018.

    Latvia, 2018-05-25 22:49 CEST (GLOBE NEWSWIRE) — Latvijas Juras medicinas centrs JSC: interim report for the 3 months of 2018, approved by the Board at 25.05.2018.            Member of the Board: Juris Imaks, phone: 29512492

     
     
  • Genmab Announces that Janssen Will Stop Studies of Daratumumab in Combination with Anti-PD-(L)1

    Genmab Announces that Janssen Will Stop Studies of Daratumumab in Combination with Anti-PD-(L)1

    Company Announcement Copenhagen, Denmark; May 26, 2018 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that following a planned review, the DMC has recommended that the Phase Ib/II study (CALLISTO/LUC2001) of daratumumab in combination with atezolizumab versus atezolizumab monotherapy in patients with previously treated advanced or metastatic non-small cell lung cancer should be terminated. In addition the phase I MMY2036 […]

     
     
  • Q3 Trading Update

    Zurich / Switzerland, 24 May 2018 ARYZTA AG announces third quarter trading and lowers FY 2018 guidance   The news release can be downloaded from the following link:   Attachment

     
     
  • Algemene Vergadering van Aandeelhouders Corbion verleent goedkeuring aan management-benoemingen en dividend

    De Algemene Vergadering van Aandeelhouders van Corbion, die op 25 mei 2018 is gehouden, heeft goedkeuring verleend aan de herbenoeming van CFO Eddy van Rhede van der Kloot voor een tweede termijn. De Raad van Commissarissen van Corbion is verheugd te kunnen aankondigen dat de overeenkomst van opdracht met Eddy van Rhede van der Kloot, CFO, wordt verlengd met een […]

     
     
  • Corbion General Shareholders Meeting approves Board reappointments and dividend

    The Corbion General Shareholders Meeting held on 25 May 2017 approved the reappointment of CFO Eddy van Rhede van der Kloot for a second term of office. Corbion‘s Supervisory Board is pleased to announce that the contract of assignment of Eddy van Rhede van der Kloot, CFO, will be extended for an additional period of 4 years (May 2018 – […]